The company's commercial testing continues to focus on patients with identified lung nodules, but the new data is the strongest yet to support a shift to upfront cancer detection.
The test will be based on MRM Proteomics' immunoMALDI approach, which uses antibody enrichment of target proteins followed by analysis via MALDI mass spec.
The approval by WHO's Expert Review Panel for Diagnostics makes the test eligible for procurement by organizations that can access Global Fund and Unitaid resources.
The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
